Research Progress of BMAL1 in Heart Failure

Area of Science:

• Cardiovascular Disease Research
• Circadian Biology
• Molecular Cardiology

Background:

• Heart failure is the end stage of cardiovascular disease, characterized by cardiac remodeling.
• Brain and muscle aryl hydrocarbon receptor nuclear translocator-like 1 (BMAL1), a core circadian gene, significantly impacts cardiac remodeling.
• BMAL1 deficiency is linked to metabolic dysfunction, cardiomyocyte hypertrophy, inflammation, fibrosis, and impaired heart function, exacerbating heart failure.

Purpose of the Study:

• To systematically review the mechanisms of BMAL1 in heart failure.
• To focus on BMAL1's regulatory roles in cardiac metabolism, inflammation, and fibrosis.
• To explore the clinical potential of circadian rhythm regulation and chronotherapy for heart failure treatment.

Main Methods:

• Systematic literature review.
• Analysis of molecular and physiological mechanisms.
• Exploration of clinical translational studies.

Main Results:

• BMAL1 deficiency promotes myocardial metabolic dysfunction, cardiomyocyte hypertrophy, inflammation, and fibrosis.
• These pathological changes driven by BMAL1 deficiency contribute to the onset and progression of heart failure.
• Disruption of circadian rhythms is a key factor in heart failure pathogenesis.

Conclusions:

• BMAL1 plays a critical role in maintaining cardiac homeostasis and preventing heart failure.
• Targeting BMAL1 and circadian rhythm pathways offers potential therapeutic strategies for heart failure.
• Chronotherapy presents a promising avenue for novel heart failure treatments.